Browse the evidence

Gastric bypass results in large and long-lasting weight loss (25-27% total body weight loss at 12-15 years) and remission of obesity-related conditions, making it suitable for patients with BMI 35-50 kg/m2, especially with type 2 diabetes or reflux.

Gastric bypass is a highly effective surgical option for patients with BMI 35-50, especially those with type 2 diabetes or reflux. It leads to large, long-lasting weight loss (25-27% at 12-15 years) and remission of obesity-related conditions.

Poly-metabolite scores derived from blood and urine metabolomics can objectively quantify ultra-processed food (UPF) intake, serving as a valid alternative to self-reported dietary assessments.

If you want to accurately track your ultra-processed food intake without relying on memory or self-reporting bias, emerging metabolomic scores offer a precise biological alternative. While currently a research tool, these scores objectively reflect your actual UPF consumption by analyzing specific metabolites in blood and urine, bypassing the common errors of dietary surveys.

Moderate carbohydrate restriction (30% energy) inducing weight loss does not negatively affect global cognition or health-related quality of life in patients with type 2 diabetes compared to a conventional diabetes diet.

If you have Type 2 Diabetes, switching to a moderate low-carb diet (around 30% of calories from carbs) for 6 weeks to lose weight will not harm your thinking abilities or how you feel about your health. It performs similarly to standard diabetic diets regarding mental well-being and cognitive function, though you may see a slight, non-significant boost in mental health scores.

Moderate carbohydrate restriction (30% energy) selectively worsens psychomotor speed (measured by SDMT) compared to a conventional diabetes diet, despite no effect on global cognition.

Be aware that switching to a moderate low-carb diet might make you feel slightly slower at processing information or performing quick mental tasks (like the Symbol Digit Test) in the first few weeks. However, this does not appear to affect your overall memory or general thinking ability, and this specific slowdown may improve with longer-term adherence.

Tirzepatide (15 mg) produces a greater improvement in insulin sensitivity per unit of weight loss compared to semaglutide (1 mg) in patients with type 2 diabetes, suggesting mechanisms beyond simple adiposity reduction.

If you are treating type 2 diabetes with GLP-1 based therapies, tirzepatide (15 mg) appears to offer superior improvements in how your body uses insulin for every pound lost, compared to semaglutide (1 mg). This suggests tirzepatide works through additional hormonal pathways (GIP/GLP-1) beyond just reducing fat mass. For patients prioritizing metabolic health improvements alongside weight loss, this distinction may be clinically relevant.

A low-carbohydrate diet may cause a significant increase in LDL cholesterol in a subset of individuals (approx. 30%), necessitating lipid monitoring despite average group stability.

If you follow a low-carb diet, get your blood work done after 3 months. If your LDL cholesterol rises significantly (especially >30% increase), consult your doctor. You may need to adjust your fat sources (e.g., more unsaturated fats) or reduce total fat intake, even if your triglycerides and HDL are improving.

GLP-1 receptor agonists (e.g., Liraglutide) reduce appetite and improve glucose tolerance by stimulating anorexigenic POMC/CART neurons and suppressing orexigenic AgRP/NPY neurons via cAMP and GABA-dependent signaling pathways.

GLP-1 based therapies work by targeting the brain's hunger centers (POMC/CART) to reduce appetite and improve blood sugar control. This suggests that obesity management can involve pharmacological support of natural hormonal signals, rather than relying solely on behavioral changes.

Sustainable, high-quality weight loss requires combining appetite suppression with moderate increases in energy expenditure and preservation of lean mass, rather than focusing solely on absolute weight reduction.

To lose weight sustainably, do not just focus on eating less. Prioritize strategies that protect your muscle mass (like resistance training and adequate protein) and support your metabolism. Modern treatments should ideally combine appetite control with mechanisms that prevent metabolic slowdown. The goal is to lose fat while keeping your lean tissue, which helps you maintain the weight loss long-term.

Testosterone therapy in transgender men leads to increased lean mass and visceral adiposity, while estrogen therapy in transgender women leads to decreased lean mass and increased fat mass, confirming the causal role of sex steroids in body composition.

If you are undergoing gender-affirming hormone therapy, expect your body composition to shift towards your new hormonal profile. Trans men will likely gain muscle and visceral fat; trans women will likely lose muscle and gain subcutaneous fat. This is a direct result of the hormones, not lifestyle failure.

Menopause triggers a shift in fat distribution from protective subcutaneous tissue to harmful visceral adipose tissue due to declining estrogen levels, increasing the risk of metabolic disease.

As you approach menopause, your body will naturally start storing more fat around your organs (visceral) rather than your hips and thighs. This increases metabolic risk. Hormone replacement therapy can partially reverse this shift, but lifestyle management of visceral fat becomes critical.

Metabolic dysfunction-associated steatotic liver disease (MASLD) is bidirectionally associated with the development and progression of cardiovascular, renal, and metabolic disorders, acting as both a driver and consequence of systemic cardiometabolic dysfunction.

If you have fatty liver (MASLD), it is not just a liver issue; it significantly increases your risk for heart disease, kidney disease, and diabetes. You need to manage your metabolic health (weight, blood sugar, blood pressure) comprehensively to protect your heart and kidneys, not just your liver.

SGLT2 inhibitors, GLP-1 receptor agonists, and finerenone demonstrate benefits across multiple cardiometabolic conditions, improving clinical outcomes in patients with MASLD, CKD, and CVD.

Current medications like SGLT2 inhibitors, GLP-1 agonists, and finerenone are effective for treating multiple aspects of cardiometabolic disease simultaneously. Discuss these options with your doctor if you have liver, kidney, or heart issues.

Higher plasma levels of Trimethylamine N-oxide (TMAO) are associated with increased risk of all-cause mortality, cardiovascular disease (CVD) mortality, and death due to kidney failure in a multi-ethnic general population.

High plasma TMAO levels are linked to higher risks of heart disease, kidney failure, and overall mortality. Since TMAO is produced by gut bacteria from nutrients in red meat and eggs, managing your intake of these foods and supporting gut health may help lower TMAO levels and potentially reduce long-term health risks. Consult with a healthcare provider for personalized advice.

GLP-1 receptor agonists cause a reduction in lean body mass (25-45% of total weight loss), which may impact mobility and metabolic rate, particularly in older adults or those with sarcopenic obesity.

When you lose weight on GLP-1 medications, you lose both fat and some muscle. About a quarter to half of your total weight loss might be muscle. This can affect your strength and metabolism, especially if you are older. To protect your muscles, focus on eating enough protein and doing resistance exercises (like weight lifting) while on the medication.

Short sleep duration (<5 hours) and long sleep duration (>9 hours) are independently associated with a significantly increased risk of acute stroke, exhibiting a U-shaped relationship where short sleep shows a higher magnitude of association on univariate analysis but attenuates more than long sleep after adjusting for comorbidities.

Aim for 7 hours of sleep per night. Both sleeping less than 5 hours and more than 9 hours is associated with a significantly higher risk of stroke. If you consistently sleep outside this range, consider it a modifiable risk factor for cardiovascular health, especially if you have other risk factors like hypertension.

Symptoms of Obstructive Sleep Apnea (snoring, snorting, breathing cessation) and a derived OSA score of 2-3 are significantly associated with increased odds of acute stroke, independent of a formal OSA diagnosis.

If you or your partner notice loud snoring, gasping, or pauses in breathing during sleep, seek medical evaluation. These symptoms are strongly linked to stroke risk, even if you haven't been diagnosed with sleep apnea. Addressing these symptoms may reduce stroke risk.

A higher cumulative burden of sleep disturbance symptoms (Sleep Disturbance Symptom Burden >5) is associated with a graded, significantly increased risk of acute stroke, with the highest burden showing an OR of 5.38.

If you experience multiple sleep problems (e.g., short/long sleep, poor quality, snoring, napping), your stroke risk increases significantly. The more symptoms you have, the higher the risk. Seek a comprehensive sleep evaluation to address all symptoms, not just one.

Saturated fatty acids (SFAs) promote inflammation and insulin resistance by activating TLR4 and inflammasomes, whereas polyunsaturated fatty acids (PUFAs) mitigate inflammation by suppressing NF-κB and upregulating anti-inflammatory IL-10.

Focus on the quality of your fats. Replace saturated fats (found in red meat, butter) with polyunsaturated fats (found in fish, nuts, olive oil). This shift can help lower inflammation and improve your body's sensitivity to insulin.

Probiotic supplementation for metabolic syndrome yields heterogeneous outcomes: a subset of 'responders' improves triglycerides and diastolic blood pressure, while 'non-responders' experience increased blood glucose and insulin levels.

If you have metabolic syndrome, a probiotic might not help everyone. In this study, some people saw better blood pressure and triglycerides, but others saw worse blood sugar. Your diet matters: responders ate more sugars and specific nutrients like folate and lactose. Before starting a probiotic for metabolic health, consider that it may not work for you, and your current diet might influence whether it helps or harms your metabolic markers.

Dietary intake, specifically higher consumption of sugars, lactose, and folate, distinguishes probiotic responders from non-responders, suggesting diet modulates probiotic efficacy.

Your diet might determine if a probiotic works for you. In this study, people who responded well to the probiotic tended to eat more sugars, lactose, and folate than those who didn't respond. This doesn't mean you should eat more sugar, but it suggests that your current diet interacts with the probiotic. If you're taking a probiotic for metabolic health, your dietary habits are a key part of the equation.

Tirzepatide (5-15 mg once weekly) significantly reduces the risk of composite kidney endpoints (eGFR decline ≥40%, renal death, kidney failure, or new-onset macroalbuminuria) in patients with type 2 diabetes and high cardiovascular risk compared to insulin glargine.

If you have type 2 diabetes and are at high risk for heart or kidney problems, tirzepatide (a once-weekly injection) has been shown to significantly reduce the risk of serious kidney issues compared to insulin glargine. This benefit includes slowing the decline in kidney function and preventing the onset of severe protein in the urine. While there may be an initial, reversible drop in kidney function numbers, this is a sign of reduced stress on the kidneys. Always consult your doctor to see if this treatment is appropriate for your specific health profile.

BCAA supplementation activates anabolic signaling pathways (mTORC1) and improves hormonal profiles (testosterone/cortisol ratio) in the short term, but this does not translate to long-term muscle or strength gains if total protein intake is adequate.

BCAAs do trigger muscle-building signals in your body, but this doesn't mean you will gain muscle or strength. If you are eating enough protein from food, BCAAs add no value. Do not use them to try to 'boost' your muscle growth.

Time-restricted eating (TRE) improves metabolic health markers (insulin sensitivity, glucose control) independent of weight loss when the eating window is aligned with circadian rhythms (early/mid-TRE), whereas late or self-selected windows show little to no benefit.

If you want to try Time-Restricted Eating, start by shifting your eating window to the earlier part of the day (e.g., 8am to 4pm or 10am to 6pm) rather than skipping breakfast or eating late at night. Keep your food choices normal (ad libitum) but ensure you finish eating before 8pm. This alignment with your body's natural circadian rhythms is what drives metabolic improvements, independent of weight loss.

Liraglutide improves insulin sensitivity (measured by HOMA-IR, HOMA2, and Matsuda index) rapidly, within 2 weeks, independent of weight loss.

If you have obesity and prediabetes, liraglutide improves how your body handles insulin within two weeks, even before you lose significant weight. This is a direct drug effect, not just a result of dieting.